Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-06-06
2003-12-30
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S069100, C435S320100, C435S455000
Reexamination Certificate
active
06670333
ABSTRACT:
BACKGROUND OF THE INVENTION
Angiogenesis is the fundamental process by which new blood vessels are formed. The process involves the migration of vascular endothelial cells into tissue, followed by the condensation of such endothelial cells into vessels. Angiogenesis may be induced by an angiogenic agent or be the result of a natural condition. The process is essential to a variety of normal body activities, such as reproduction, development and wound repair. Although the process is not completely understood, it involves a complex interplay of molecules that stimulate and molecules that inhibit the growth and migration of endothelial cells, the primary cells of the capillary blood vessels. Under normal conditions, these molecules appear to maintain the microvasculature in a quiescent state (i.e., without capillary growth) for prolonged periods which can last for several years or even decades. The turnover time for an endothelial cell is about 1,000 days. Under appropriate conditions, however (e.g., during wound repair), these same cells can undergo rapid proliferation and turnover within a much shorter period, and five days is typical under these circumstances. (Folkman and Shing,
J. Biol. Chem.,
267(16), 10931-34 (1989); Folkman and Klagsbrun,
Science,
235, 442-47 (1987)).
Although angiogenesis is a highly regulated process under normal conditions, many diseases (characterized as “angiogenic diseases”) are driven by persistent unregulated angiogenesis. In such disease state, unregulated angiogenesis can either cause a particular disease directly or exacerbate an existing pathological condition. For example, ocular neovascularization has been implicated as the most common cause of blindness and underlies the pathology of approximately 20 eye diseases. In certain previously existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous humor, causing bleeding and blindness.
Both the growth and metastasis of solid tumors are also angiogenesis-dependent (Folkman,
J. Cancer Res.,
46, 467-73 (1986); Folkman,
J. Nat. Cancer Inst.,
82, 4-6 (1989); Folkman et al., “Tumor Angiogenesis,” Chapter 10, pp. 206-32, in
The Molecular Basis of Cancer
, Mendelsohn et al., eds. (W. B. Saunders, 1995)). It has been shown, for example, that tumors which enlarge to greater than 2 mm. in diameter must obtain their own blood supply and do so by inducing the growth of new capillary blood vessels. After these new blood vessels become embedded in the tumor, they provide nutrients and growth factors essential for tumor growth as well as a means for tumor cells to enter the circulation and metastasize to distant sites, such as liver, lung or bone (Weidner,
New Eng. J. Med.,
324(1), 1-8 (1991)). When used as drugs in tumor-bearing animals, natural inhibitors of angiogenesis can prevent the growth of small tumors (O'Reilly et al., O'Reilly et al.,
Cell,
79, 315-28 (1994)). Indeed, in some protocols, the application of such inhibitors leads to tumor regression and dormancy even after cessation of treatment (O'Reilly et al.,
Cell,
88, 277-85 (1997)). Moreover, supplying inhibitors of angiogenesis to certain tumors can potentiate their response to other therapeutic regimens (e.g., chemotherapy) (see, e.g., Teischer et al.,
Int. J. Cancer,
57, 920-25 (1994)).
Although several angiogenesis inhibitors are currently under development for use in treating angiogenic diseases (Gasparini,
Eur. J. Cancer,
32A(14), 2379-85 (1996)), there are disadvantages associated with several of these proposed inhibitory compounds. For example, suramin is a potent angiogenesis inhibitor, but, at doses required to reach antitumor activity, causes severe systemic toxicity in humans. Other compounds, such as retinoids, interferons and antiestrogens appear safe for human use but have only a weak anti-angiogenic effect. Still other compounds may be difficult or costly to make. In view of these problems, there exists a need for methods and compositions for inhibiting angiogenesis.
BRIEF SUMMARY OF THE INVENTION
The present invention provides a method of inhibiting angiogenesis within a tissue by providing exogenous SLED (an antiangiogenic protein) to endothelial cells associated with the tissue. The presence of exogenous SLED will inhibit angiogenesis within the tissue, in part by interfering with the ability of vascular endothelia to expand within the tissue. The invention also provides a method for determining the prognosis of a tumor by assaying for the presence of SLED within the tumor. To facilitate the inventive method, the present invention provides pharmaceutical compositions including sources of SLED.
The methods and compositions of the present invention are clinically useful for treating a host of diseases associated with angiogenesis, and for interfering with angiogenesis associated with reproductive functions. The methods and compositions are also diagnostically useful for assessing the prognosis of tumors and other disorders associated with angiogenesis. Furthermore, the methods and compositions are useful reagents for investigation of angiogenesis in the laboratory setting. These and other advantages of the present invention, as well as additional inventive features, will be apparent from the accompanying drawings and in the following detailed description.
REFERENCES:
patent: 4996159 (1991-02-01), Glaser
patent: WO93/24529 (1993-12-01), None
patent: WO95/33480 (1995-12-01), None
Dawson et al., Science, vol. 285, 1999, pp. 245-248.*
Alberdi and Becerra, Invest. Ophthalmol. Vis. Sci., 37, S791 (1996) (abstract #3642).
Alberdi et al., Biochemistry, 37, 10643-10652 (1998).
Araki et al., J. Neurosci. Res., 53, 7-15 (1998).
Bain et al., Gene Therapy, 1, S68.
Barany et al., J. Peptide Protein Res., 30, 705-739 (1987).
Becerra, “Structure-Function Studies on PEDF” Chapter 21 in Chemistry and Biology of Serpins, Church et al., eds. (Plenum Press, 1997).
Becerra et al., J. Biol. Chem., 268, 23148-23156 (1993).
Becerra et al., J. Biol. Chem., 270, 25992-99 (1995).
Berns and Giraud, Annals NY Acad. Sci., 772, 95-104 (1995).
Casey and Li, Am. J. Ophthalmol., 124, 521-529 (1997).
Chader et al., Invest. Ophthalmol. Vis. Sci., 37, S791 (1996) (abstract #3641).
DiPaolo et al., Exp. Cell Res., 220, 173-185 (1995).
Doggett et al., Mech. Ageing Dev., 65, 239-255 (1992).
Feher et al., Invest. Ophthalmol. Vis. Sci., 38, S591 (1997) (abstract #2753).
Fink et al., Annu. Rev. Neurosci., 19, 265-287 (1996).
Folkman et al., “Tumor Angiogenesis”, Chapter 10, pp. 206-232 in The Molecular Basis of Cancer, Mendelsohn et al., eds. (WB Saunders, 1995).
Folkman, Cancer Res., 46, 467-73 (1986).
Folkman, J. Nat. Cancer Inst., 82,4-6 (1989).
Folkman and Klagsbrun, Science, 235, 442-47 (1987).
Folkman and Shing, J. Biol Chem., 267 (16), 10931-34 (1989).
Gasparini, Eur. J. Cancer, 32A (14), 2379-85 (1996).
Gastl et al., Oncology, 54, 177-184 (1997).
Goliath et al., Molecular Vision, 2:5 (1996).
Jiang et al., J. Invest. Dermatol., 104, 523-25 (1995).
Kozaki et al., J. Biol. Chem., 273, 15125-15130 (1998).
Kyritsis et al., Exp. Eye Res., 38, 411-421 (1984).
Merrifield, J. Am. Chem. Soc., 85, 2149-2154 (1963).
O'Reilly et al, Cell 88, 277-85 (1997).
O'Reilly et al., Cell, 79, 315-28 (1994).
Ortego et al., Invest. Ophthalmol. Vis. Sci., 37, 2759-2767 (1996).
Palmieri et al., Proc. Am. Assoc. Cancer Res., 38, 587 (1997) (abstract #3940).
Paus et al., Lab Invest. 71, 134-40 (1994).
Paus et al., Lab Invest. 60, 365-69 (1989).
Perez-Mediavilla et al., Biochim. Biophys. Acta, 1398, 203-214 (1998).
Phillips et al., Cancer Res., 56, 606-611 (1996).
Pignolo et al., J. Biol. Chem., 268, 8949-8957 (1993).
Pignolo et al., J. Cell. Physiol., 162, 110-118 (1995).
Potempa et al., J. Biol. Chem., 269, 15957-15960 (1994).
Rakmilevich et al., PNAS, 93, 6291-96 (1996).
Rubin, Nature Med., 2, 632-633 (1996).
Shirozu et al., Genomics, 37, 273-280 (1996).
Singh et al., Invest. Ophthalmol. Vis. Sci., 38, S5
Bouck Noel P.
Dawson David W.
Gillis Paul R.
Guzo David
Morgan & Lewis & Bockius, LLP
Northwestern University
LandOfFree
Methods and compositions for inhibiting angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibiting angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibiting angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3151454